↓ Skip to main content

A Randomized Trial of Nafamostat for Covid-19

Overview of attention for article published in NEJM Evidence, October 2023
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (84th percentile)
  • Above-average Attention Score compared to outputs of the same age and source (57th percentile)

Mentioned by

twitter
18 X users

Readers on

mendeley
28 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.

Login to access the Attention Digest and the Sentiment Analysis related to this output.

Timeline Attention over time Attention Score history
Login to access the full charts related to this output.
Activity
Login to access the full charts related to this output.
X Demographics

X Demographics

The data shown below were collected from the profiles of 18 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley demographics

Mendeley demographics

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Login to view Mendeley reader trends over time.

Geographical breakdown

Geographical breakdown
Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status
Readers by professional status Count As %
Lecturer 3 11%
Student > Doctoral Student 3 11%
Student > Bachelor 2 7%
Unspecified 1 4%
Librarian 1 4%
Other 4 14%
Unknown 14 50%
Readers by discipline
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 3 11%
Medicine and Dentistry 3 11%
Environmental Science 2 7%
Nursing and Health Professions 2 7%
Unspecified 1 4%
Other 3 11%
Unknown 14 50%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 11. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 June 2024.
All research outputs
#4,163,758
of 31,733,458 outputs
Outputs from NEJM Evidence
#320
of 551 outputs
Outputs of similar age
#57,653
of 378,283 outputs
Outputs of similar age from NEJM Evidence
#15
of 35 outputs
Altmetric has tracked 31,733,458 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 551 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 71.3. This one is in the 41st percentile – i.e., 41% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 378,283 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 84% of its contemporaries.
We're also able to compare this research output to 35 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.